Aurinia Pharmaceuticals Inc.
AUPH Nasdaq Pharmaceutical Preparations Financials FY2018–FY2025
Revenue
Total sales reported in the income statement.
$283M
20.4%
vs prior year
Operating margin
Operating income as a share of revenue.
37.1%
39.1 pts
Net income
Profit after all expenses, interest and tax.
$287M
4,893.1%
Free cash flow
Cash from operations minus capital spending.
—
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
—
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
On $2.29 EPS (TTM)
What Aurinia Pharmaceuticals Inc. does
No business description yet.
- Legal name
- Aurinia Pharmaceuticals Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Accession · CIK
- 0001600620-26-000017
0001600620
Revenue and margins
Aurinia Pharmaceuticals Inc. had $283M of revenue in fiscal 2025, up 20.4% on the year before.
FY18
Revenue $0.5M
FY19
Revenue $0.3M
FY20
Revenue $50.1M
FY21
Revenue $45.6M
FY22
Revenue $134M
FY23
Revenue $176M
FY24
Revenue $235M
FY25
Revenue $283M
Q3 '23
Revenue $54.5M
Q4 '23
Revenue $45.1M
Q1 '24
Revenue $50.3M
Q2 '24
Revenue $57.2M
Q3 '24
Revenue $67.8M
Q4 '24
Revenue $59.9M
Q1 '25
Revenue $62.5M
Q2 '25
Revenue $70.0M
Q3 '25
Revenue $73.5M
Q4 '25
Revenue $77.1M
Q1 '26
Revenue $77.7M
Q2 '26
Revenue $83.2M
FY18
Gross —
Operating −11,930.9%
Net −11,464.1%
FCF —
FY19
Gross 100.0%
Operating −28,598.4%
Net −27,794.0%
FCF —
FY20
Gross 100.0%
Operating −208.1%
Net −204.9%
FCF —
FY21
Gross 97.6%
Operating −396.3%
Net −396.8%
FCF —
FY22
Gross 95.8%
Operating −83.2%
Net −80.7%
FCF —
FY23
Gross 91.9%
Operating −52.2%
Net −44.5%
FCF —
FY24
Gross 88.0%
Operating −2.0%
Net 2.4%
FCF —
FY25
Gross 88.5%
Operating 37.1%
Net 101.5%
FCF —
Gross
Operating
Net
FCF
Q3 '23
Gross 87.6%
Operating −29.8%
Net −24.7%
FCF —
Q4 '23
Gross 88.0%
Operating −65.8%
Net −59.6%
FCF —
Q1 '24
Gross 84.6%
Operating −26.3%
Net −21.4%
FCF —
Q2 '24
Gross 84.4%
Operating −2.6%
Net 1.3%
FCF —
Q3 '24
Gross 91.1%
Operating 17.3%
Net 21.2%
FCF —
Q4 '24
Gross 90.7%
Operating −2.8%
Net 2.4%
FCF —
Q1 '25
Gross 86.3%
Operating 35.0%
Net 37.4%
FCF —
Q2 '25
Gross 89.8%
Operating 28.7%
Net 30.7%
FCF —
Q3 '25
Gross 88.9%
Operating 40.5%
Net 42.9%
FCF —
Q4 '25
Gross 88.6%
Operating 43.1%
Net 273.4%
FCF —
Q1 '26
Gross 91.6%
Operating 53.3%
Net 44.2%
FCF —
Q2 '26
Gross 92.1%
Operating 55.7%
Net 45.0%
FCF —
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY18
Net income −$53.1M
FY19
Net income −$88.4M
FY20
Net income −$103M
FY21
Net income −$181M
FY22
Net income −$108M
FY23
Net income −$78.0M
FY24
Net income $5.8M
FY25
Net income $287M
Q3 '23
Net income −$13.4M
Q4 '23
Net income −$26.9M
Q1 '24
Net income −$10.7M
Q2 '24
Net income $0.7M
Q3 '24
Net income $14.4M
Q4 '24
Net income $1.4M
Q1 '25
Net income $23.3M
Q2 '25
Net income $21.5M
Q3 '25
Net income $31.6M
Q4 '25
Net income $211M
Q1 '26
Net income $34.4M
Q2 '26
Net income $37.4M
FY18
Diluted EPS −$0.63
FY19
Diluted EPS −$0.95
FY20
Diluted EPS −$0.87
FY21
Diluted EPS −$1.40
FY22
Diluted EPS −$0.76
FY23
Diluted EPS −$0.54
FY24
Diluted EPS $0.04
FY25
Diluted EPS $2.07
Q3 '23
Diluted EPS −$0.09
Q4 '23
Diluted EPS −$0.19
Q1 '24
Diluted EPS −$0.07
Q2 '24
Diluted EPS $0.01
Q3 '24
Diluted EPS $0.10
Q4 '24
Diluted EPS $0.01
Q1 '25
Diluted EPS $0.16
Q2 '25
Diluted EPS $0.16
Q3 '25
Diluted EPS $0.23
Q4 '25
Diluted EPS $1.53
Q1 '26
Diluted EPS $0.25
Q2 '26
Diluted EPS $0.28
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY18
Return on capital —
Return on equity −39.1%
Return on assets —
FY19
Return on capital —
Return on equity −40.7%
Return on assets −27.3%
FY20
Return on capital —
Return on equity −29.1%
Return on assets −26.1%
FY21
Return on capital —
Return on equity −40.8%
Return on assets −35.9%
FY22
Return on capital —
Return on equity −24.5%
Return on assets −21.3%
FY23
Return on capital —
Return on equity −19.9%
Return on assets −15.3%
FY24
Return on capital —
Return on equity 1.5%
Return on assets 1.0%
FY25
Return on capital —
Return on equity 59.9%
Return on assets 44.1%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
FY18
Free cash flow —
FY19
Free cash flow —
FY20
Free cash flow —
FY21
Free cash flow —
FY22
Free cash flow —
FY23
Free cash flow —
FY24
Free cash flow —
FY25
Free cash flow —
FY18
Cash from operations −$51.6M
Capital spending —
FY19
Cash from operations −$63.6M
Capital spending —
FY20
Cash from operations −$69.9M
Capital spending —
FY21
Cash from operations −$158M
Capital spending —
FY22
Cash from operations −$79.5M
Capital spending —
FY23
Cash from operations −$33.5M
Capital spending —
FY24
Cash from operations $44.4M
Capital spending —
FY25
Cash from operations $136M
Capital spending —
Cash from operations
Capital spending
Q3 '23
Cash from operations −$13.3M
Capital spending —
Q4 '23
Cash from operations $14.3M
Capital spending —
Q1 '24
Cash from operations −$18.6M
Capital spending —
Q2 '24
Cash from operations $15.8M
Capital spending —
Q3 '24
Cash from operations $17.0M
Capital spending —
Q4 '24
Cash from operations $30.1M
Capital spending —
Q1 '25
Cash from operations $1.3M
Capital spending —
Q2 '25
Cash from operations $44.2M
Capital spending —
Q3 '25
Cash from operations $44.4M
Capital spending —
Q4 '25
Cash from operations $45.7M
Capital spending —
Q1 '26
Cash from operations $32.6M
Capital spending —
Q2 '26
Cash from operations $52.6M
Capital spending —
Cash from operations
Capital spending
Dividends, buybacks and share count
Aurinia Pharmaceuticals Inc. returned $98.2M to shareholders in fiscal 2025. The diluted share count fell 5.1%.
FY18
Dividends —
Buybacks —
FY19
Dividends —
Buybacks —
FY20
Dividends —
Buybacks —
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks $0.0M
FY23
Dividends —
Buybacks $0.0M
FY24
Dividends —
Buybacks $40.2M
FY25
Dividends —
Buybacks $98.2M
Dividends
Buybacks
Q3 '23
Dividends —
Buybacks $0.0M
Q4 '23
Dividends —
Buybacks $0.0M
Q1 '24
Dividends —
Buybacks $12.3M
Q2 '24
Dividends —
Buybacks $6.1M
Q3 '24
Dividends —
Buybacks $0.0M
Q4 '24
Dividends —
Buybacks $21.8M
Q1 '25
Dividends —
Buybacks $46.9M
Q2 '25
Dividends —
Buybacks $42.6M
Q3 '25
Dividends —
Buybacks $8.7M
Q4 '25
Dividends —
Buybacks $0.0M
Q1 '26
Dividends —
Buybacks $36.2M
Q2 '26
Dividends —
Buybacks $38.7M
Dividends
Buybacks
FY18
Diluted shares 0.08B
FY19
Diluted shares 0.09B
FY20
Diluted shares 0.12B
FY21
Diluted shares 0.13B
FY22
Diluted shares 0.14B
FY23
Diluted shares 0.14B
FY24
Diluted shares 0.15B
FY25
Diluted shares 0.14B
Balance sheet
Cash, debt and the ratios that show how comfortably Aurinia Pharmaceuticals Inc. can carry it.
FY18
Cash $118M
Debt —
FY19
Cash $306M
Debt —
FY20
Cash $272M
Debt —
FY21
Cash $232M
Debt —
FY22
Cash $94.1M
Debt —
FY23
Cash $48.8M
Debt —
FY24
Cash $83.4M
Debt —
FY25
Cash $80.2M
Debt —
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $232M | $94.1M | $48.8M | $83.4M | $80.2M |
| Interest coverage | — | — | −33.0x | −1.0x | 24.2x |
| Current ratio | 12.6x | 9.6x | 5.5x | 4.6x | 5.2x |
| Quick ratio | 12.2x | 9.1x | 5.0x | 4.2x | 4.8x |
| Total assets | $543M | $471M | $548M | $551M | $752M |
| Total liabilities | $64.3M | $65.4M | $170M | $173M | $170M |
| Shareholders' equity | $479M | $405M | $378M | $377M | $581M |
| Net debt (− = net cash) | — | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✓ | ✓ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✓ | ✓ |
| Return on assets rose | — | — | ✓ | ✕ | ✓ | ✓ | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✕ |
| Debt fell relative to assets | — | — | — | — | — | — | — | — |
| Current ratio rose | — | — | ✕ | ✕ | ✕ | ✕ | ✕ | ✓ |
| Share count didn't rise | — | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✓ |
| Gross margin rose | — | — | ✕ | ✕ | ✕ | ✕ | ✕ | ✓ |
| Revenue rose relative to assets | — | — | ✓ | ✕ | ✓ | ✓ | ✓ | ✕ |
| F-score | — / 3 | — / 4 | 3 / 8 | 1 / 8 | 3 / 8 | 3 / 8 | 5 / 8 | 6 / 8 |
| Accruals ratio | — | −7.6% | −8.3% | −4.6% | −5.6% | −8.7% | −7.0% | 23.3% |
| Altman Z'' | — | 11.71 | 7.58 | 6.76 | 4.46 | −0.24 | 0.84 | 5.18 |
8 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0.5M | $0.3M | $50.1M | $45.6M | $134M | $176M | $235M | $283M |
| Gross profit | — | $0.3M | $50.1M | $44.5M | $128M | $161M | $207M | $250M |
| Research and development | $41.4M | $52.9M | $50.3M | $51.1M | $45.0M | $49.6M | $20.8M | $32.5M |
| Operating income | −$55.2M | −$90.9M | −$104M | −$181M | −$111M | −$91.7M | −$4.7M | $105M |
| Interest expense | — | — | — | $0.0M | $0.0M | $2.8M | $4.8M | $4.3M |
| Pretax income | −$53.0M | −$88.2M | −$103M | −$180M | −$106M | −$77.5M | $7.4M | $114M |
| Income tax | $0.1M | $0.1M | −$0.1M | $0.8M | $1.8M | $0.6M | $1.7M | −$173M |
| Net income | −$53.1M | −$88.4M | −$103M | −$181M | −$108M | −$78.0M | $5.8M | $287M |
| Diluted EPS | −$0.63 | −$0.95 | −$0.87 | −$1.40 | −$0.76 | −$0.54 | $0.04 | $2.07 |
| Diluted shares | 0.08B | 0.09B | 0.12B | 0.13B | 0.14B | 0.14B | 0.15B | 0.14B |
| Cash flow | ||||||||
| Cash from operations | −$51.6M | −$63.6M | −$69.9M | −$158M | −$79.5M | −$33.5M | $44.4M | $136M |
| Depreciation and amortization | $0.0M | $0.0M | $1.4M | $2.8M | $2.7M | $11.6M | $19.4M | $19.4M |
| Stock-based compensation | $6.9M | $7.4M | $17.5M | $31.2M | $32.3M | $45.3M | $31.6M | $14.7M |
| Share buybacks | — | — | — | — | $0.0M | $0.0M | $40.2M | $98.2M |
| Dividends and buybacks | — | — | — | — | $0.0M | $0.0M | $40.2M | $98.2M |
| Balance sheet | ||||||||
| Cash and short-term investments | $118M | $306M | $272M | $232M | $94.1M | $48.8M | $83.4M | $80.2M |
| Finance lease liabilities | — | — | — | — | — | $90.1M | $72.6M | $68.8M |
| Current assets | — | $315M | $419M | $513M | $443M | $425M | $447M | $492M |
| Current liabilities | — | $11.3M | $32.0M | $40.6M | $46.1M | $77.2M | $97.8M | $93.7M |
| Inventory | — | $0.0M | $13.9M | $19.3M | $24.8M | $39.7M | $39.2M | $45.7M |
| Property and equipment, net | — | $0.1M | $4.8M | $4.4M | $3.7M | $3.4M | $2.7M | $2.1M |
| Intangible assets | — | $8.9M | $9.3M | $8.4M | $6.4M | $5.0M | $4.4M | $3.8M |
| Total assets | — | $324M | $464M | $543M | $471M | $548M | $551M | $752M |
| Total liabilities | — | $25.7M | $55.9M | $64.3M | $65.4M | $170M | $173M | $170M |
| Shareholders' equity | $136M | $299M | $408M | $479M | $405M | $378M | $377M | $581M |
| Margins | ||||||||
| Gross margin | — | 100.0% | 100.0% | 97.6% | 95.8% | 91.9% | 88.0% | 88.5% |
| Operating margin | −11,930.9% | −28,598.4% | −208.1% | −396.3% | −83.2% | −52.2% | −2.0% | 37.1% |
| EBITDA margin | −11,926.6% | −28,588.1% | −205.4% | −390.3% | −81.1% | −45.6% | 6.3% | 43.9% |
| Net margin | −11,464.1% | −27,794.0% | −204.9% | −396.8% | −80.7% | −44.5% | 2.4% | 101.5% |
| Returns | ||||||||
| Return on capital employed | — | −29.1% | −24.2% | −36.0% | −26.2% | −19.5% | −1.0% | 15.9% |
| Return on equity | −39.1% | −40.7% | −29.1% | −40.8% | −24.5% | −19.9% | 1.5% | 59.9% |
| Return on assets | — | −27.3% | −26.1% | −35.9% | −21.3% | −15.3% | 1.0% | 44.1% |
| Return on tangible equity | −39.1% | −30.5% | −25.8% | −38.4% | −27.1% | −20.9% | 1.5% | 49.7% |
| Growth | ||||||||
| Revenue growth | — | −31.3% | 15,660.4% | −9.0% | 193.9% | 31.0% | 34.0% | 20.4% |
| Net income growth | — | — | — | — | — | — | — | 4,893.1% |
| EPS growth | — | — | — | — | — | — | — | 5,075.0% |
| Share count change | — | 9.7% | 27.4% | 9.2% | 9.7% | 0.9% | 2.1% | −5.1% |
| Financial health | ||||||||
| Interest coverage | — | — | — | — | — | −33.0x | −1.0x | 24.2x |
| Current ratio | — | 27.9x | 13.1x | 12.6x | 9.6x | 5.5x | 4.6x | 5.2x |
| Quick ratio | — | 27.9x | 12.7x | 12.2x | 9.1x | 5.0x | 4.2x | 4.8x |
| Capital allocation | ||||||||
| Stock comp / revenue | 1,481.6% | 2,331.4% | 34.8% | 68.5% | 24.1% | 25.8% | 13.4% | 5.2% |
| Quality scores | ||||||||
| Piotroski F-score | — | — | 3.0 | 1.0 | 3.0 | 3.0 | 5.0 | 6.0 |
| Altman Z'' | — | 11.7 | 7.6 | 6.8 | 4.5 | −0.2 | 0.8 | 5.2 |
| Accruals ratio | — | −7.6% | −8.3% | −4.6% | −5.6% | −8.7% | −7.0% | 23.3% |
Source: SEC EDGAR XBRL filings (CIK 0001600620). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.